NewzThe president of the Spanish Association of Pediatrics (AEP), Dr. Luis Carlos Blesa, has stated that GLP-1 receptor agonist medications should be publicly funded to ensure equity in the treatment of childhood obesity. According to the AEP leadership, these pharmaceutical treatments ought to be incorporated as an additional medical tool in addressing the growing public health challenge of obesity among minors.
The proposition emphasizes the need for equitable access to modern pharmacological interventions for young patients. By framing the inclusion of these drugs as a matter of fairness, the pediatric association highlights disparities in patient care and the necessity of integrating advanced therapeutic options into standard healthcare coverage for children.
In-depth summary · AI, neutral